At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 597 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Inhaled Treprostinil 6 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)
In Brief
A Phase 3 clinical trial evaluating Placebo, Inhaled Treprostinil, and 1 other intervention for Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease. Completed, enrolled 597 participants across 108 sites in 16 countries.
Detailed Summary
Study RIN-PF-303 is a multinational study designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Belgium, Chile, Denmark, France, Germany, Israel, Italy, Mexico, Netherlands, New Zealand, Peru, South Korea, Spain, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedFeb 2022
Enrollment StartOct 2022
Primary CompletionJun 2025
TodayJul 2026
First PostedFeb 25, 2022
Enrollment StartOct 4, 2022
Primary CompletionJun 30, 2025
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 4.4 years ago
Interventions
Placebodrug
Placebo administered QID
Inhaled Treprostinildrug
Inhaled treprostinil (6 mcg/breath) administered QID
Treprostinil Ultrasonic Nebulizerdevice
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.